Skip to content

Endothelin Concentrations in a Population With Cardiovascular Disease and Periodonitis

Analysis of Endothelin Concentrations in a Population With Cardiovascular Disease and Periodontitis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04152005
Enrollment
165
Registered
2019-11-05
Start date
2016-01-01
Completion date
2018-09-30
Last updated
2019-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Serum; Disease

Brief summary

Recently, a key role played in the ethiology of periodontitis has been highlighted by a Endothelin (ET-1). ET1 possess the ability to express surface antigens of endothelial and hematopoietic stem cells and to assist in maintaining vascular integrity and the repair mechanism of the endothelium. ET originate from bone marrow

Detailed description

The aim of the present study was to investigate the association between ET-1 in patients with periodontitis. Furthermore, the objective was to determine if the periodontal status influenced ET-1 levels.

Interventions

OTHERObservation

Evaluation of ET-1 level and correlation of ET-1 levels with periodontal and cardiovascular disease

Sponsors

University of Messina
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
21 Years to 71 Years

Inclusion criteria

* Presence of at least 16 teeth * CP with a minimum of 40% of sites with a clinical attachment level (CAL) ≥2mm and probing depth (PD) ≥4mm; * Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs * Presence of ≥40% sites with bleeding on probing (BOP)

Exclusion criteria

* Intake of contraceptives * Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study * Status of pregnancy or lactation * Previous history of excessive drinking * Allergy to local anaesthetic * Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of ET-1 levels1 yearCorrelation of ET-1 levels with periodontal and cardiovascular disease

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026